REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
29/06/2026
Voltar para busca
Dado oficial do USPTO
HHHBIO
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
27
Atualização mais recente
29/06/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
10/07/2020
Data de registro
29/06/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
29/06/2021
Última transação
29/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
16
Localização do titular
KR
Examinador
KETCHUM, BRENDAN J
Unidade examinadora
N70
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a stylized word "HHHBio" which consists of the three overlapped "H"s connected to "B" in green and "i" and "o" in red.
Titulares e representantes
Titulares
3H Bio. Co., Ltd.
Representantes
Paul G. Johnson Maschoff Brennan
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Drugs for medical purposesdrugs for the treatment of oncological and metabolic diseases and disorders; medicines for human purposesmedicine for the treatment of infectious diseases; medicines for human purposesmedicine for the treatment of viral diseases and disorders; medicines for human purposesmedicine for the treatment of respiratory diseases and disorders; therapeutic drugs and agentstherapeutic drugs for the treatment of immune system related diseases and disorders; pharmaceutical preparations for preventing and treating obesity; vaccines; human vaccine preparations; pharmaceutical agents affecting metabolism; protein for medical purposesprotein arrays for diagnosing cancer; protein for medical purposesprotein arrays for diagnosing allergies; peptide for medical purposessynthetic peptides for the treatment of immune system related diseases and disorders; synthetic protein for the treatment of diabetes; synthetic protein for the treatment of oncological and metabolic diseases and disorders; synthetic peptide for the treatment of obesity; synthetic peptide for the treatment of viral diseases and disorders; pharmaceutical preparations containing peptides as the active ingredientspharmaceutical preparations for the treatment of neurological diseases and disorders
Classe 42
Research relating to pharmaceuticalspharmaceutical research services; medicine researchresearch and development of medicines; medical analysis services of peptide for the treatment of people; research for medical productsnamely medical research; chemical research; biological research; laboratory research in the field of pharmaceuticals; clinical studies of medicinesconducting clinical trials for others; operation of medical laboratorymedical laboratory services; scientific research for medical purposes; research and development of peptide for medical purposes; research of biology; research and development of peptide for scientific or laboratory purposes; drug discovery services; research and development of technology for biotechnology; development of pharmaceutical preparations and medicines
Publicações
Histórico de despachos e eventos da marca no USPTO.
27 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
28/01/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
23/11/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
28/10/2021
FIMP
FINAL DISPOSITION PROCESSED
28/10/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
29/09/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
29/06/2021
GPNX
NOTIFICATION PROCESSED BY IB
13/04/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
13/04/2021
PUBO
PUBLISHED FOR OPPOSITION
13/04/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
24/03/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
24/03/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
24/03/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/03/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/03/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/03/2021
RFNT
REFUSAL PROCESSED BY IB
01/03/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/02/2021
RFRR
REFUSAL PROCESSED BY MPU
05/02/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
20/01/2021
CNRT
NON-FINAL ACTION WRITTEN
19/01/2021
MAFR
APPLICATION FILING RECEIPT MAILED
16/01/2021
DOCK
ASSIGNED TO EXAMINER
12/01/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/01/2021
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
11/01/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
24/12/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace HHHBIO ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.